These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 17264329)

  • 21. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma.
    Casella R; Shariat SF; Monoski MA; Lerner SP
    Cancer; 2002 Dec; 95(12):2494-9. PubMed ID: 12467062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers.
    Shariat SF; Karam JA; Walz J; Roehrborn CG; Montorsi F; Margulis V; Saad F; Slawin KM; Karakiewicz PI
    Clin Cancer Res; 2008 Jun; 14(12):3785-91. PubMed ID: 18559597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of urokinase-type plasminogen activator and its receptor in plasma of patients with cerebral infarction].
    Song SJ; Hu JB; Wang HX; Wen SQ; Ding MP; Huang JZ
    Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(18):1583-5. PubMed ID: 14642114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue urokinase-type plasminogen activator receptor levels in breast cancer.
    Gong SJ; Rha SY; Chung HC; Yoo NC; Roh JK; Yang WI; Lee KS; Min JS; Kim BS; Chung HC
    Int J Mol Med; 2000 Sep; 6(3):301-5. PubMed ID: 10934293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo.
    Rabbani SA; Gladu J
    Cancer Res; 2002 Apr; 62(8):2390-7. PubMed ID: 11956102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
    Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
    Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ; Duggan C
    Clin Biochem; 2004 Jul; 37(7):541-8. PubMed ID: 15234235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder.
    Shariat SF; Monoski MA; Andrews B; Wheeler TM; Lerner SP; Slawin KM
    Urology; 2003 May; 61(5):1053-8. PubMed ID: 12736046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
    Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
    Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perineural invasion is a prognostic factor for biochemical failure after radical prostatectomy.
    Jeon HG; Bae J; Yi JS; Hwang IS; Lee SE; Lee E
    Int J Urol; 2009 Aug; 16(8):682-6. PubMed ID: 19602004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer.
    Miyake H; Hara I; Yamanaka K; Gohji K; Arakawa S; Kamidono S
    Prostate; 1999 May; 39(2):123-9. PubMed ID: 10221568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy.
    Shariat SF; Svatek RS; Kabbani W; Walz J; Lotan Y; Karakiewicz PI; Roehrborn CG
    BJU Int; 2008 Jan; 101(2):232-7. PubMed ID: 17868422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
    Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
    Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.